FMP
OncoCyte Corporation
OCX
NASDAQ
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
2.08 USD
-0.04 (-1.92%)
2023
2022
2021
2020
1.5M
958k
7.73M
1.22M
1.09M
976k
7.54M
1.85M
413k
-18k
188k
-639k
25.64M
30.31M
47.13M
33.08M
9.29M
7.3M
13.63M
9.8M
13.54M
23.01M
33.5M
23.28M
2.79M
1.13M
11.17M
6.49M
10.74M
21.88M
22.34M
16.79M
2.72M
-67k
-37k
27k
-25.14M
-18M
-46.95M
-29.71M
281k
-615k
854k
-1.48M
-24.86M
-18.61M
-73.36M
-31.19M
0
54.83M
-9.26M
-1.25M
-27.78M
-73.44M
-64.1M
-29.93M
-3.75
-13.26
-14.42
-9.14
-3.75
-13.26
-14.42
-9.14
7.65M
5.54M
4.45M
3.27M
7.65M
5.54M
4.45M
3.27M
-23.12M
-13.31M
-48.46M
-30.54M
2023
2022
2021
2020
-260.68M
-187.77M
-123.68M
-93.75M
-27.78M
-73.44M
-64.1M
-29.93M
-1.12M
0
-239k
-14k
0
0
0
0
-289.88M
-260.68M
-187.77M
-123.68M
-30.32M
-72.9M
-64.34M
-29.95M
2023
2022
2021
2020
5.44M
10.85M
8.53M
6.52M
1.68M
5.22M
4.21M
394k
-281k
-4.34M
-2.25M
-1.23M
4.04M
9.97M
6.57M
7.36M
2023
2022
2021
2020
0
-18.68M
9.5M
9.19M
0
18.68M
9.19M
0
0
0
18.68M
9.19M
All figures are in USD.